PolynovoASX:PNV -3.70%76 ROE % is 0.01% as of Dec. 2025. GuruFocus rates ASX:PNV with a GF Score™ of 76/100 and a GF Value™ of A$3.24 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Polynovo ranks better than 80.35% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Polynovo's annualized net income for the quarter that ended in Dec. 2025 was A$0.0 Mil. Polynovo's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was A$83.2 Mil. Therefore, Polynovo's annualized ROE % for the quarter that ended in Dec. 2025 was 0.01%.
The historical rank and industry rank for Polynovo's ROE % or its related term are showing as below:
ASX:PNV'
s ROE % Range Over the Past 10 Years
Min: -38.62 Med: -14.33 Max: 17.01
Current: 12.25
During the past 13 years, Polynovo's highest ROE % was 17.01%. The lowest was -38.62%. And the median was -14.33%.
ASX:PNV's ROE % is ranked better than 80.35% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs ASX:PNV: 12.25
Polynovo (ASX:PNV) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Polynovo ROE % Related Terms
Polynovo ROE % Historical Data
* Premium members only.
The historical data trend for Polynovo's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's ROE % distribution charts can be found below:
* The bar in red indicates where Polynovo's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Polynovo (ASX:PNV) has a ROE % of 0.01% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #157 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 19.6%.
Is Polynovo's ROE % too high?
Polynovo's current ROE % is 0.01%. The Medical Devices & Instruments industry median ROE % is 2.42. Polynovo's value of 0.01% is 99.6% below this industry median. Based on the distribution chart, Polynovo ranks #157 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Polynovo has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #157 out of 799 companies for ROE %. This places Polynovo in the top 20% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Polynovo's value of 0.01% is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current ROE % of 0.01% is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current ROE % is 0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (ASX:PNV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$3.24, compared to a current price of A$0.91 — trading 71.9% below its estimated fair value. The current ROE % is 0.01% and 99.6% below the Medical Devices & Instruments industry median of 2.42. Polynovo's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Polynovo (ASX:PNV), the current ROE % is 0.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (ASX:PNV) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of A$0.91 is trading 71.9% below its estimated GF Value™ of A$3.24.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for ASX:PNV:
ROE %: 0.01%
GF Value™: A$3.24 vs. price of A$0.91 (71.9% below fair value)
Industry Position: 99.6% below the Medical Devices & Instruments median (#157 of 799)
No single metric tells the full story. See the ASX:PNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
76GF Score
Get the complete analysis for ASX:PNV
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PNV has been successfully added to your 
